Introduction
============

Glaucoma is characterized by progressive optic neuropathy leading to severe, often permanent, vision loss \[[@r1]\]. Glaucoma is considered one of the major causes of bilateral blindness worldwide, with an estimated prevalence of 64.3 million, of whom 8.4 million are bilaterally blind \[[@r2]\]. This prevalence is anticipated to rise with an alarming rate to 76.0 million in 2020 and 111.8 million in 2040 \[[@r3],[@r4]\]. Among the glaucoma subtypes, primary congenital glaucoma (PCG; OMIM [231300](https://www.ncbi.nlm.nih.gov/omim/?term=231300)), characterized by the presence of an underdeveloped trabecular meshwork, is an imperative cause of severe visual disability in children, and has a prevalence of 1:10,000 to 18,000 live births worldwide \[[@r2]\].

In PCG, the improperly developed aqueous outflow system results in increased intraocular pressure, enlargement (Buphthalmos) and opacification of cornea, edema, with an ultimate consequence of optic nerve damage and vision impairment \[[@r5],[@r6]\]. PCG is a genetically heterogeneous disorder, and commonly segregates in a typical autosomal recessive fashion. However, linkage and positional cloning studies have also revealed autosomal dominant PCG loci or genes \[[@r5]\]. Among the known genes, biallelic variants of *CYP1B1* (OMIM 601,771) and *LTBP2* (OMIM 602,091) are the common cause of PCG worldwide \[[@r5],[@r7],[@r8]\]. As of September 2018, around 240 and 26 pathogenic variants of *CYP1B1* and *LTBP2*, respectively, are listed in the [Human Gene Mutation database](http://www.hgmd.cf.ac.uk/ac/index.php). In patients with PCG, early diagnosis is important for effective treatment of the disease with surgical interventions (e.g., trabeculotomy, trabeculectomy, goniotomy, or deep sclerectomy), use of drainage implants, or correcting refractive errors and amblyopia. Therefore, identifying individuals at risk for inheriting pathogenic variant(s) as soon as possible after birth has considerable ramifications for diagnosis, management, and treatment of PCG and to prevent unnecessary health care costs \[[@r5]\].

To investigate the etiology of the disease at the molecular level and to improve genetic diagnosis, we ascertained a large cohort of consanguineous Pakistani families segregating PCG. We performed candidate genes screening with Sanger sequencing and whole exome sequence (WES) analysis to identify the underlying genetic cause of PCG in the cohort. In this study, we report identification of five known and three novel variants of *CYP1B1* segregating in 14 families with PCG. We did not find a pathogenic allele in *CYP1B1* and *LTBP2* in 22 of the 36 families (61%), which suggests genetic heterogeneity of PCG in the Pakistani population.

Methods
=======

Subjects and clinical evaluation
--------------------------------

The present study was approved by IRB committees of the participating institutions in the United States and Pakistan. All methods used in the study followed the precepts of Declaration of Helsinki and were in compliance of the ARVO statement on human subjects. Informed written consent was obtained from all individuals before inclusion in the study. A total of 423 individuals including 227 males (of which 79 had glaucoma) and 196 females (71 affected) with the ages ranging from 1 year old to 65 years old were recruited from Sindh and Punjab Provinces of Pakistan. Detailed interviews were conducted with family members to gather information on pedigree structure, comorbidities, onset of disease, and initial symptoms. The clinical diagnosis was based on presenting symptoms, physical and ophthalmic examinations, fundoscopy, or slit-lamp microscopy. The DNA was extracted from whole blood by using the inorganic method as described previously Grimberg et al 1989 \[[@r9]\].

Known genes screening and exome sequencing
------------------------------------------

Before exome sequencing, we performed Sanger sequencing on one affected individual from 24 of the 36 families with glaucoma for known PCG genes, *CYP1B1* and *LTBP2*. Primers for Sanger sequencing were designed using Primer3. PCR amplification was performed as follows: 95 °C: 2 min (1X), 95 °C: 30 sec; annealing temperature: 30 sec; 72 °C: 1 min (35X), 72 °C: 7 min (1X), 25 °C: 5 min (1X) by using EconoTaq Plus 2X Master mix. and DNA sequencing were performed as described previously \[[@r10]\]. WES was performed on the remaining 12 families and on the families negative for pathogenic variants in *CYP1B1* and *LTBP2*. For WES, genomic libraries were recovered for exome enrichment using the Agilent SureSelect Human Expanded All Exon V5 (62 Mb) kit (Agilent corporation, Santa Clara, CA).. Libraries were sequenced on an Illumina HiSeq2500 (Agilent corporation) with average 100X coverage. Data analysis used the Broad Institute's Genome Analysis Toolkit \[[@r11]\]. Reads were aligned with the Illumina Chastity Filter with the Burrows-Wheeler Aligner \[[@r12]\]. Variant sites were called using the GATK UnifiedGenotyper module. Single nucleotide variant calls were filtered using the variant quality score recalibration method \[[@r11]\]. Filtration of candidate variants was performed as described previously \[[@r13]\]. Sanger sequencing was used to confirm the segregation of the variants identified in the families.

In silico analysis
------------------

The following online pathogenicity prediction programs were used to evaluate the pathogenicity of missense variants: Polymorphism Phenotyping v2 ([PolyPhen-2](http://genetics.bwh.harvard.edu/pph2/)), Sorting Tolerant From Intolerant ([SIFT](http://sift.jcvi.org/)), [Mutation Taster](http://www.mutationtaster.org/index.html), [Mutation Assessor](http://mutationassessor.org/), and [fathmm](http://fathmm.biocompute.org.uk/). Moreover, ClustalW alignment was used to assess the conservation of the affected amino acid residues.

Results
=======

Clinical findings
-----------------

In this study, we enrolled 36 families segregating with primary congenital glaucoma from the Punjab and Sindh provinces of Pakistan ([Figure 1](#f1){ref-type="fig"}). The neonatal clinical records of the affected individuals were not available at the time of enrollment. According to the family history, all the affected individuals were reported to have vision problems shortly after birth or in early childhood. The most common features consistent with PCG included high intraocular pressure, reduced visual acuity, increased corneal diameter, and corneal haze ([Figure 1](#f1){ref-type="fig"}, [Table 1](#t1){ref-type="table"}). However, high inter- and intrafamilial variability was observed in the severity of PCG in these families ([Table 1](#t1){ref-type="table"}). For instance, one affected individual of family PKED05 had no apparent visual impairment or corneal haze, but ophthalmic evaluation revealed high intraocular pressure, while the other affected individuals of the same family had classical symptoms of PCG. Furthermore, a few affected individuals of the families with PCG had low vision and corneal haze only in one eye ([Table 1](#t1){ref-type="table"}). However, a few of the participating affected individuals had microphthalmia, and were completely blind at the time of enrollment.

![Pedigrees of Pakistani families with PCG with segregated variants in *CYP1B1*. Pedigrees of 14 multigenerational families who segregated recessive primary congenital glaucoma (PCG) due to disease-causing variants in *CYP1B1*. Filled and empty symbols represent affected and unaffected individuals, respectively. A double line connecting two individuals represents consanguineous marriage. Genotypes are written at the bottom of the enrolled individuals. Shown also are eye photographs of representative affected individuals. All the affected individuals have hazy corneas.](mv-v25-144-f1){#f1}

###### Clinical details of the families segregating CYP1B1 variants.

  Family ID   Participant IDs   Age (Yrs)   Variant               IOP (mmHg) OS/OD   Visual Acuity OS/OD   Surgical procedure                   Medicine used for IOP   Remarks
  ----------- ----------------- ----------- --------------------- ------------------ --------------------- ------------------------------------ ----------------------- ---------------------------------------------------------
  PKED01      IV 6              7           c.542T\>A             14/14              NA                    Trabeculectomy                       Yes                     Cornea clear, well-formed bleb
              IV 12             6           p.(Leu181Gln)         NA                 NA                    Trabeculectomy                       Yes                     OS/OD CD= 0.9
              IV 15             13                                22/20              NA                    Trabeculectomy                       Yes                     NA
              IV 18             1                                 17/17              NA                    Trabeculectomy                       Yes                     NA
  GCFGL02     III:1             4           c.868dupC             25/53              PL:NPL                Corneal scraping                     Yes                     Bilateral corneal haze
                                            p.(Arg290Profs\*37)                                            Trabeculectomy                                               Enlarged anterior segment
              III:2             7                                 18/29              PL:NPL                Corneal scraping                     yes                     Bilateral corneal haze
                                                                                                           Trabeculectomy                                               Enlarged anterior segment
  GCUF22      IV:2              5           c.1168C\>T            33/30              NPL: NPL              No                                   No                      Severe corneal haze
                                            p.(Arg390Cys)                                                                                                               Habb's striae
              IV:3              3                                 29/21              NPL: NPL              OS: Trabeculectomy                   No                      Deep anterior segment bilateral
                                                                                                           OD: No                                                        
  LUCC20      IV:5              30          c.1169G\>A            NR/15              NPL: NPL              Trabeculectomy                       No                      Bilateral corneal haze
              IV:6              24          p.(Arg390His)         32/28              NR: NR                Trabeculectomy                       Yes                     Bilateral corneal haze
                                                                                                                                                                         
  LUPCG04     V:2               17          c.1169G\>A            30/NR              NPL: NPL              Trabeculectomy                       Yes                     Bilateral corneal haze
                                            p.(Arg390His)                                                                                                                
              V:5               34                                NR/NR              NPL: NPL              No                                   No                      Bilateral corneal haze
  LUPCG16     V:5               13          c.1169G\>A            40/35              NPL: NPL              No                                   No                      NA
                                            p.(Arg390His)                                                                                                                
  GCFGL01     III:2             13          c.1169G\>A            18/20              NPL: NPL              Trabeculectomy                       Yes                     OS/OD severe corneal haze
              III:4             5           p.(Arg390His)         32/29              NPL: NPL              Trabeculectomy                       No                      OS: Habb's Striae buphthalmol
                                                                                                                                                                        OD: sever corneal haze
              III:5             10                                NA/26              NPL:20/50             No                                   No                      OS: phthisis occurred
                                                                                                                                                                        OD: severe corneal haze Enlarged anterior segment
  GCUF10      IV:1              3           c.1169G\>A            28/24              20/100:20/70          Trabeculectomy                       Yes                     OS/OD Haze Cornea, AGV
              IV:2              5           p.(Arg390His)         29/26              20/70:20/70           Trabeculectomy                       Yes                     OS/OD Haze Cornea, AGV
  GCUF23      III:1             22          c.1169G\>A            NA/16              NPL: NPL              No                                   No                      OS: phthisis occurred
                                            p.(Arg390His)                                                                                                               OD: severe haze cornea
              III:4             43                                                   NPL: NPL              No                                   No                      OS: severe corneal haze, deep cup
                                                                                                                                                                        OD: phthisis occurred
              III:5             40                                26/NA              NPL: NPL              No                                   No                      OS: severe corneal haze
                                                                                                                                                                        OD: phthisis occurred
              IV:2              30                                20/NA              PL: NPL               No                                   No                      OS: deep cup
                                                                                                                                                                        OD: phthisis occurred
              IV:3              27                                21/16              PL: NPL               No                                   No                      OS: deep cup
                                                                                                                                                                        OD: severe corneal haze
              V:4               1.5                               14062              PL:PL                 Lansectomy and Anterior Vetrectomy   No                      OS: AGV done
                                                                                                                                                                        OD: AGV done, Opaque cornea
  GCUF19      IV:6              30          c.1209insTCATGCCACC   NA/16              NPL:20/100            Goniotomy                            No                      OS: phthisis occurred
                                            p.(Thr404Serfs\*30)                                                                                                         OD: deep cup
              IV:7              25                                43804              1/60: PL              Trabeculectomy                       No                      OS/OD deep cup
              IV:8              10                                26/27              NPL: NPL              Trabeculectomy                       Yes                     OS/OD deep cup
              V:1               3                                 20/17              20/70:20/50           Trabeculectomy                       Yes                     severe corneal haze
  LUPCG10     IV:8              11          c.1310C\>T            14/17              OS 6/24               Trabeculectomy                       Yes                     OS/OD CD= 0.8/0.9
                                            p.(Pro437Leu)                            OD 6/18                                                                             
  LUPCG01     III:6             15          c.1325delC            30/28              OS 6/20               Trabeculectomy                       Yes                     OS/OD CD= 0.6/0.5
                                            p.(Pro442Glufs\*10)                      OD 6/10                                                                             
              III:7             25                                25/25              OS 6/24               Trabeculectomy                       Yes                     OS/OD CD= 0.7/0.6
                                                                                     OD 6/24                                                                             
  GCUF14      V:4               25          PCG                   35/33              NPL: NPL              No                                   No                      severe corneal haze
              V:7               18          PCG                   30/32              NPL: NPL              No                                   No                      severe corneal haze
              V:11              27          PCG                   NA                 NPL: NPL              No                                   No                      OS/OD phthisis occurred
  GCFGL01     III:2             13          PCG                   18/20              NPL: NPL              Trabeculectomy                       Yes                     OS/OD severe corneal haze
              III:4             5           PCG                   32/29              NPL: NPL              Trabeculectomy                       No                      OS: Habb's Striae buphthalmol
                                                                                                                                                                        OD: sever corneal haze
              III:5             10          PCG                   NA/26              NPL:20/50             No                                   No                      OS: phthisis occurred
                                                                                                                                                                        OD: severe corneal haze enlarged anterior segment
  PKED05      III 2             18          PCG                   NA                 NPL                   Trabeculectomy                       Yes                     OS: phthisis Bulbi
                                                                                                                                                                        OD: phthisis Bulbi
              III 6             13          PCG                   34/44              0.266666667           No                                   Yes                     OS/OD CD= 1.0/0.8
                                                                                                                                                                        MG negative
              III 7             11          PCG                   16/20              NA                    No                                   Yes                     opaque cornea in both eyes
                                                                                                                                                                        OD: leukocoria
              IV 1              1           PCG                   NA                 PL:PL                 Trabeculectomy                       Yes                     photophobia, large eye balls, OS/OD severe corneal haze

NPL: no light perception; PL: light perception; NA: not accessible due to phthisis; AGV: Ahmed's glaucoma valve; TC: total cupping; NR: not recordable. IOP: Intraocular pressure; MG: myasthenia gravis; CD: cup-to-disc ratio

Genetic spectrum
----------------

We used candidate genes (*CYP1B1* and *LTBP2*) screening and WES to identify the underlying genetic causes of PCG in the families. We identified eight variants of *CYP1B1* cosegregating with PCG in 14 of the 36 families ([Figure 1](#f1){ref-type="fig"}, [Table 2](#t2){ref-type="table"}). All of these 14 consanguineous families segregated PCG associated with *CYP1B1* variants in a homozygous fashion. Five of these variants have been previously reported to cause PCG in humans, but we also identified three novel variants in *CYP1B1* ([Table 2](#t2){ref-type="table"}). Almost 75% (six of eight) of the identified variants are present only once in the cohort ([Table 2](#t2){ref-type="table"}). However, a single variant p.(Arg390His) was found in six of the 14 families with *CYP1B1*-associated PCG ([Table 2](#t2){ref-type="table"}). Surprisingly, we did not find a disease-associated variant of *LTBP2* in the cohort, which suggests genetic heterogeneity of PCG in Pakistani families.

###### *CYP1B1* alleles identified in this study.

  Family                                              Nucleotide change     Amino acid change     CADD   SIFT       Polyphen2           MutationTaster    Mutation Assessor   Fathmm      gnomAD     Reference
  --------------------------------------------------- --------------------- --------------------- ------ ---------- ------------------- ----------------- ------------------- ----------- ---------- ------------
  PKED01                                              c.542T\>A             p.(Leu181Gln)         23.6   Damaging   Probably damaging   Disease causing   Medium              Tolerated   0          This study
  PKED05                                              c.1436 A\>G           p.(Gln479Arg)         11     Damaging   Probably damaging   Disease causing   Medium                          0          This study
  LUPCG01, GCUF14                                     c.1325delC            p.(Pro442Glufs\*15)   \-     NA         NA                  NA                NA                  NA          4.06E-06   This study
  LUCC20, LUPCG04, LUPCG16, GCFGL01, GCUF10, GCUF23   c.1169G\>A            p.(Arg390His)         35     Damaging   Probably damaging   Disease causing   High                Damaging    0.000102   \[[@r27]\]
  LUPCG10                                             c.1310C\>T            p.(Pro437Leu)         33     Damaging   Probably damaging   Disease causing   High                Damaging    2.16E-05   \[[@r27]\]
  GCFGL02                                             c.868dupC             p.(Arg290Profs\*37)   34     NA         NA                  NA                NA                  NA          2.31E-05   \[[@r28]\]
  GCUF19                                              c.1209InsTCATGCCACC   p.(Thr404Serfs\*30)   25.5   NA         NA                  NA                NA                  NA          0.000199   \[[@r29]\]
  GCUF22                                              c.1168C\>T            p.(Arg390Cys)         34     Damaging   Probably damaging   Disease causing   NA                  Damaging    3.63E-05   \[[@r30]\]

NA: Not available; CADD: Combined annotation dependent depletion.

Causal variants
---------------

Of the causative variants identified in this study, two were novel missense variants \[p.(Leu181Gln and p.(Gln479Arg)\] of *CYP1B1*, cosegregating with PCG in families PKED01 and PKED05, respectively ([Figure 1](#f1){ref-type="fig"}). These missense variants were not found in the Genome Aggregation (gnomAD), Human Gene Mutation (HGMD), and ClinVar databases, and were predicted to be deleterious by various in silico prediction algorithms ([Table 2](#t2){ref-type="table"}). Both missense variants affected amino-acid residues that are highly conserved among the CYP1B1 orthologs ([Figure 2](#f2){ref-type="fig"}). We also used the HOPE \[[@r14]\] and Phyre2 \[[@r15]\] 3D modeling prediction programs to further assess the effects of these two missense variants on the secondary structure of the encoded protein. The p.Leu181 and p.Gln479 residues are located in the cytochrome p450 domain. Leucine at position 181 is part of an α-helix and is predicted to be buried in the protein core. Substitution of p.Leu181 with glutamine, which is smaller and less hydrophobic than leucine, does not prefer an α-helix as a secondary structure and leads to the loss of hydrophobic interactions in the protein core. Similarly, the substituting glutamine with arginine at position 479 is predicted to affect the protein stability by introducing protein-folding problems due to its positive charge, which, in turn, could affect the ligand contacts made by one of the neighboring residues.

![Multiple sequences alignment of CYP1B1 orthologs and molecular modeling of missense variants. **A**: ClustalW alignment of CYP1B1 proteins shows conservation of the residues at positions 181, 290, 390, 404, 437, 442, and 479 among eight species. **B**: Predicted three-dimensional (3D) structures of wild-type and mutant CYP1B1 proteins created using Phyre2. The positions of the wild-type and mutated forms of the amino acids in this cohort are shown in green and red, respectively. The p.Leu181 residue of CYP1B1 is located in the α-helix of the secondary structure, and replacing this residue with a smaller, less hydrophobic glutamine residue is predicted to slightly destabilize the local conformation and leads to the loss of hydrophobic interactions in the protein core. Modeling of the cytochrome domain of CYP1B1 revealed that the p.Arg390 residue forms a hydrogen bond and a salt bridge with glutamic acid at position 387, asparagine at position 428, and proline at position 437. Substitution with smaller residue histidine \[p.(Arg390His)\] or cysteine \[p.(Arg390Cys)\] is predicted to disrupt this hydrogen bond, and interrupt the signal transduction between the two domains of CYP1B1, cause an empty space in the core of the protein, and distort the correct protein folding. The p.Pro437 residue is located on the protein's surface. Prolines are known to be rigid and therefore, induce a special backbone conformation. Replacing a proline with leucine might disturb this special conformation and distort the interactions with other molecules. Finally, the substituting glutamine with arginine at position 479 is predicted to affect the protein stability by introducing protein-folding problems due to its positive charge, which, in turn, could affect the ligand contacts made by one of the neighboring residues.](mv-v25-144-f2){#f2}

In two families with PCG (LUPCG01 and GCUF14), we found a novel single nucleotide deletion (c.1325delC), which is predicted to cause premature truncation \[p.(Pro442Glufs\*15); [Table 2](#t2){ref-type="table"}) of the encoded protein. This variant has low frequency in gnomAD (4.061 × 10^−6^), but is not registered in HGMD or ClinVar. In two other families (GCFGL02 and GCUF19), we identified two known frameshift variants \[c.868dupC, p.(Arg290Profs\*37); c.1209InsTCATGCCACC, p.(Thr404Serfs\*30)\], respectively. Both insertion variants are also predicted to result in premature stop codons and early truncation of CYP1B1.

In this study, the most commonly observed variant was c.1169G\>A \[p.(Arg390His)\], which was found cosegregating with PCG in six families ([Table 2](#t2){ref-type="table"}). The c.1169G\>A variant has relatively low frequency in the gnomAD database (1.017 × 10^−4^), which includes data of 123,136 exome and 15,496 whole-genome sequences. Therefore, we performed a haplotype analysis using eight closely linked single nucleotide polymorphisms (SNPs) in *CYP1B1* to identify potential founder effects for this recurrent variant. Selection of these eight SNPs for haplotype analysis was based on the observance of high heterozygosity (\>0.3) in 50 control samples randomly collected from the Pakistani population. The results were consistent with a common ancestor for the c.1169G\>A recurrent allele in the Pakistani families in this study (data not shown).

The arginine at position 390 is highly conserved across *CYP1B1* orthologs ([Figure 2A](#f2){ref-type="fig"}), and is predicted to be protein damaging by several in silico bioinformatics tools ([Table 2](#t2){ref-type="table"}). The 3D protein modeling revealed that the p.Arg390 forms a hydrogen bond and a salt bridge with glutamic acid at position 387, asparagine at position 428, and proline at position 437 ([Figure 2B](#f2){ref-type="fig"}). Substitution with a smaller residue histidine \[p.(Arg390His)\] is predicted to disrupt this hydrogen bond, and interrupt the signal transduction between the two domains of CYP1B1, and thus, is predicted to be pathogenic. In another family with PCG (GCUF22), arginine at position 390 is substituted with cysteine \[p.(Arg390Cys); [Table 2](#t2){ref-type="table"}\], which is also predicted to result in the loss of charge required to keep ionic interactions to make a salt bridge. The p.(Arg390Cys) substitution is also predicted to cause an empty space in the core of the protein and loss of hydrogen bonds and distort the correct protein folding.

Finally, through WES we identified a known missense variant \[c.1310C\>T, p.(Pro437Leu)\] of the *CYP1B1* gene in family LUPCG10 ([Table 2](#t2){ref-type="table"}). The proline residue at position 437 is located on the protein's surface. As proline is rigid, p.Pro437 is predicted to induce a special protein backbone conformation at this position. The p.(Pro437Leu) substitution might disturb this special conformation and distort the interactions with other molecules.

Discussion
==========

PCG is one of the most common genetic diseases worldwide. Pathogenic variants in *CYP1B1* represent a broad spectrum for PCG at the global level. *CYP1B1* is a constituent of cytochrome p450 family genes that are known to be involved in the detoxification of exogenous and endogenous molecules. CYP1B1 also plays a role in developmental processes of eye with an influence on metabolism. In ocular development, retinoic acid and estradiols are the two specific substrates for *CYP1B1* \[[@r16]\]. *CYP1B1* is known to regulate oxidative homeostasis, and ultrastructural and functional performance of trabecular meshwork tissue in the eye \[[@r17]\].

This study described the identification of eight allelic variants of *CYP1B1* in 14 families with PCG ascertained from different regions of Pakistan. All of these variants were either substitution of the highly conserved residues or predicted to cause early truncation of the encoded protein with determined functional significance, and thus, considered to be disease causing. All of the identified variants segregated with the phenotype with an autosomal recessive pattern of inheritance. Seven of these variants were found only in one to two families, except the p.(Arg390His) allele, which was recurrently found in six families and likely originated from a single ancestral modification incidence. We also identified two novel homozygous missense variants \[p.(Leu181Glu and p.(Gln479Arg)\] in PKED01 and PKED05, respectively. Each variant results in a disturbed protein local secondary structure.

Ophthalmic evaluation of the affected individuals harboring homozygous variants in *CYP1B1* revealed inter- and intrafamilial variability in the severity of PCG in these families. Variability in the disease manifestation and incomplete penetrance of *CYP1B1* alleles have been previously found in consanguineous populations in Saudi Arabia and Pakistan \[[@r18],[@r19]\]. It is possible that environmental or other epigenetic factors may be the cause of this incomplete penetrance. However, a possible dominant modifier locus has also been proposed \[[@r18]\], although no modifier gene has been reported yet. Genetically mapping a modifier variant of *CYP1B1* in humans is challenging because of the usual limitations in the number of family subjects with incomplete penetrance \[[@r18],[@r19]\]. Currently, we also cannot rule out the possibility of multiple modifier factors, including genetic and environmental, leading to incomplete penetrance. Modifiers that suppress a mutant phenotype of a Mendelian disorder provide insight into the mechanisms by which organisms can buffer biologic processes to accommodate the adverse effects of genetic mutations \[[@r20]-[@r24]\]. Thus, identification of the modifier of *CYP1B1* may point toward possible therapies for individuals with PCG.

Considering the reported frequency of *LTBP2* alleles in patients with PCG negative for variants in *CYP1B1* \[[@r7],[@r25]\], it is surprising that we did not find a pathogenic variant in the coding exons or in the splice junctions of *LTBP2* in the PCG cohort. There are several possible reasons for our failure to detect variants of *LTBP2* and *CYP1B1* in the remaining 22 families with PCG. For instance, disease-causing variants may alter the sequence of *cis*-acting regulatory or splicing elements of *LTBP2* or *CYP1B1* that are necessary for their expression in ocular tissue. Presently, we do not know the location of the regulatory elements of *CYP1B1* and *LTBP2*. Moreover, these results further support the genetic heterogeneity of PCG in the Pakistani population. Currently, we are investigating the exome data of the remaining 22 families with PCG for pathogenic variants at loci (*GLC3B*; OMIM [600975](https://www.ncbi.nlm.nih.gov/omim/?term=600975) and *GLC3C*; OMIM [613085](https://www.ncbi.nlm.nih.gov/omim/?term=613085)) that were previously linked with PCG \[[@r26],[@r27]\], as well as in genes that were not previously associated with glaucoma.

In summary, we identified three novel and five known variants of *CYP1B1* that are associated with PCG in 14 Pakistani families. The data suggest that the variants in *CYP1B1* might be responsible for extensive PCG cases in a highly consanguineous population. Detailed functional evaluation of pathogenic variants in *CYP1B1* will add to better awareness of the PCG disease mechanism. This study extends the knowledge spectrum of PCG at the molecular level and could lead to the improvement of clinically relevant genetic diagnostic protocols.
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